Search PubMed⌕ Search

Biomedical subjects

F I Lee

Publications and source records attributed to F I Lee.

At least 37 records · Page 2Linked to original sources
PubMed1987

A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report.

Colchicine (1 mg/day), or an identical placebo, was given to 64 patients with primary biliary cirrhosis in a double-blind controlled trial. Due to a novel, pair-matched trial design, the two groups were exceptionally well matched at entry. In comparison with placebo, colchicine produced a beneficial effect on serum albumin and bilirubin levels at 3 months in patients who had abnormal liver function (bilirubin greater than 20 mumol/l) at entry: (albumin, P = 0.047; bilirubin, P = 0.022). In patients with normal liver function at entry (bilirubin less than 20 mumol/l), beneficial effects were noted on total globulin levels at 3 months (P = 0.013) and on immunoglobulin G levels at 3 and 6 months (P = 0.044 and 0.001, respectively). At 18 months, survival estimate in the colchicine and placebo groups were 84% and 69%, respectively. The difference did not reach significance. Colchicine produced an early improvement in liver function and immunoglobulin levels. Few serious side effects were encountered, and colchicine clearly merits long-term study in the treatment of primary biliary cirrhosis.

Bilirubin↗
PubMed1987

Crohn's disease of late onset in Blackpool.

Fifty five (26%) of two hundred and fifteen patients presenting with Crohn's disease in the Blackpool area over a 15 year period (1969-1983) were over 60 years of age. There were twice as many women as men (38:17). In 60% disease was limited to the large bowel compared to only 29% in the younger age group. Many of these were women with mild distal colitis. Twenty one patients required operative management. In general, the prognosis was good in colonic disease, but in small bowel and ileocolonic disease the necessity for early operative intervention was potentially fatal. Delayed diagnosis, poor nutritional state and associated disease were relevant adverse factors. The majority of patients at the time of review were well and, where necessary, were coping satisfactorily with a stoma.

Age Factors↗
PubMed1986

Acute treatment of duodenal ulcer: a multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night.

A randomised double blind clinical trial was undertaken in the UK and Ireland to compare ranitidine 300 mg given as a single bed time tablet with ranitidine 150 mg twice daily in the acute treatment of duodenal ulcers. Of the 594 patients with endoscopically diagnosed duodenal ulcer entered into the trial, 424 patients had complete endoscopic findings on which healing rates at four weeks were determined. By this time 156 of 201 (78%) patients healed with ranitidine 300 mg nocte compared with 186 of 223 (83%) receiving ranitidine 150 mg twice daily (p = 0.28). After eight weeks of treatment 97% of the patients in each group were healed. The healing rates for smokers and non-smokers did not differ significantly at either four or eight weeks. Each regimen was equally effective in reducing day and night-time pain. Adverse events were reported in 23 patients overall; 12 were withdrawn from the trial. Minor abnormalities in liver function tests were noted in three patients. The trial confirmed that a single dose of ranitidine 300 mg given at night is a safe, effective alternative treatment to ranitidine 150 mg bd for the acute treatment of duodenal ulcer.

Clinical Trials as Topic↗
PubMed1985

Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers.

120 patients were randomly allocated to receive ranitidine 150 mg twice daily or a tri-potassium di-citrato bismuthate (TDB) tablet four times a day in a trial comparing the effects of these drugs in the short-term healing and post-healing relapse rates of duodenal ulceration. At 4 weeks 81% of those on ranitidine and 90% of those on TDB had healed ulcer craters. At 8 weeks 97% of those on ranitidine and 97% of those on TDB had healed. These differences are not significant. After ulcer healing, the cumulative rates of relapse, as determined endoscopically, for symptomatic and symptomless ulcers were 74% for ranitidine and 41% for TDB at 4 months (p less than 0.001), 87% for ranitidine and 55% for TDB at 8 months (p less than 0.001), and 89% for ranitidine and 62% for TDB at 12 months (p less than 0.001). Females had significantly lower relapse rates than males. In the ranitidine group smokers had a higher rate of early relapse and failure to remain healed at 12 months than did non-smokers; no such difference occurred in the TDB-treated group.

Adult↗
PubMed1985

Crohn's disease in Blackpool--incidence and prevalence 1968-80.

The occurrence of Crohn's disease has been studied in a population of approximately 300,000 in Blackpool, a seaside town in the north of England, and the surrounding area. Between 1968 and 1980, 156 patients resident in the area were diagnosed as having Crohn's disease - an annual incidence of 4 per 10(5). For the years 1971-75, the incidence was 3.3 per 10(5) and for 1976-80 it was 6.1 per 10(5). The trend is upwards but there was an apparent fall in incidence in 1974-75. In 1979 there was a peak incidence of 8 per 10(5). Over the period of study, there was an increase in all three anatomical types, small intestinal, large intestinal, and mixed disease but this increase was most marked for purely large intestinal disease. Of the 156 cases, 35% had small intestinal disease at presentation, 35% had large intestinal disease and 30% had mixed disease. The overall sex ratio was female to male 1.89:1 but highest for large bowel disease -2.6:1. Analysis of age at presentation at different sites shows a unimodal distribution for small intestinal and mixed disease with a peak in the third and fourth decades. Large bowel Crohn's disease shows a bimodal distribution with peaks in the third and eighth decades. During the period of study we identified 185 cases of Crohn's disease in the study population. On 31 December 1980, 141 patients with the condition were living, a prevalence of 47 per 10(5).

Adolescent↗
PubMed1985

Congenital hepatic fibrosis and adult-type autosomal dominant polycystic kidney disease in a child.

This reports a family with congenital hepatic fibrosis and adult polycystic kidney disease. Adult polycystic kidney disease was present in three generations. In addition, congenital hepatic fibrosis occurred in two members of the third generation. These conditions are generally held to have different modes of inheritance and the significance of their occurrence together is not clear.

Adolescent↗
PubMed1984

Ranitidine and cimetidine in prevention of duodenal ulcer relapse. A double-blind, randomised, multicentre, comparative trial.

In a comparative trial of preventive medication for duodenal ulceration with 51 participating centres, 484 patients were recruited for a year's maintenance treatment with the recommended bedtime dose of ranitidine (150 mg; n = 243) or cimetidine (400 mg; n = 241). These outpatients had recently healed duodenal ulcers, confirmed by endoscopy before and after healing, and ulcer relapse was monitored by endoscopy every 4 months. The distribution of factors likely to influence ulcer recurrence was similar in the two treatment groups. A life-table method of analysis showed that the ulcer relapse rate was consistently and significantly lower on ranitidine that on cimetidine (8% v 21%, p = 0.0018 at 4 months; 14% v 34%, p less than 0.0001 at 8 months; and 23% v 37%, p = 0.004 at 12 months). Crude relapse rate calculations, which underestimate the probability of ulcer recurrence, also confirmed the significant superiority of ranitidine 150 mg over cimetidine 400 mg nightly in preventing ulcer recurrence throughout the year.

Adult↗
PubMed1984

Ranitidine: prophylaxis of duodenal ulcer recurrence.

Ninety-two patients with healed duodenal ulcer received prophylactic treatment with ranitidine, 150 mg at night, to prevent relapse. Patients were reviewed at 4-monthly intervals for clinical assessment and endoscopy. Eighty-two patients completed the trial. After one year sixty-two patients (76%) were in endoscopic remission; ten patients (12%) suffered symptomatic relapse and ten others had asymptomatic ulcers during treatment. There were no clinically significant untoward effects associated with the drug. A single nocturnal dose of 150 mg ranitidine reduces the relapse rate after duodenal ulcer healing.

Adult↗
PubMed1983

Screening for colorectal cancer in a factory-based population with Fecatest.

This report concerns a screening programme for colorectal cancer using Fecatest, a relatively sensitive test for faecal occult blood, in a factor-based population. A total of 2420 workers between 40 and 65 years of age returned kits for testing following suitable dietary restriction. In Factory A, in which screening was offered as part of an annual medical examination, 989 men agreed to participate, a compliance rate of 45%. In Factory B, in which screening was offered in their weekly pay packets, 1431 men participated, a compliance rate of 22%. An overall positivity rate of 5.8% was found, 4.6% in Factory A and 6.6% in Factory B. Five cancers were found, two of the rectum, one at the recto-sigmoid junction, one in the sigmoid colon and one in the transverse colon. Two of these lesions were at Dukes Stage A, one at Stage B and two at Stage C. In addition, 25 adenomatous polyps were found in 17 men. In 13 these were characterized as tubular adenomata and in 4 as tubulovillous adenomata. The mean age at diagnosis in the polyp cases was 52.6 years and in the cancer cases 58.8 years. Increased specificity is obtained by excluding participants below 46 years of age. The detection rate in the 46-65 year range is approximately 1 in 100 for adenomatous polyps and 1 in 300 for cancer in the population screened. This detection rate is higher than most comparable studies using a less sensitive Guaiac test on older populations.

Adult↗
PubMed1983

Ranitidine compared with cimetidine in the short-term healing of duodenal ulcer.

The efficacy of ranitidine (150 mg twice daily) and cimetidine (200 mg three times daily and 400 mg at night) in the short-term healing of duodenal ulcer has been assessed in a randomized controlled trial involving 106 patients. There were 3 drop-outs. Forty-two out of 53 patients (79%) treated with ranitidine had healed ulcers at 4 weeks compared with 37 out of 50 treated with cimetidine (74%). This difference is not significant. At 8 weeks the healing rate for ranitidine (98%) was significantly greater than that for cimetidine (86%) (P less than 0.05). There was no significant difference in healing rates between men and women and between smokers and non-smokers. Side effects were not a problem with either drug. There were no differences of clinical significance between laboratory values in the two treatment groups, although a minor increase in mean creatinine levels occurred in the cimetidine-treated group.

Adult↗